Abstract
A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity, was very low (0.1%). This finding is consistent with limited community transmission and provides robust evidence to support New Zealand’ s successful elimination strategy for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the School of Medicine Foundation (University of Auckland), and the COVID-19 Innovation Acceleration Fund (Ministry of Business, Innovation and Employment).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health and Disability Ethics Committees New Zealand
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, NJM, upon reasonable request.
